HUTCHMED (China) (HCM) Income towards Parent Company (2014 - 2021)
HUTCHMED (China) (HCM) posted quarterly Income towards Parent Company of $61.0 million for Q2 2021, up 165.04% year-over-year from $23.0 million in Q2 2020, and up 47.65% quarter-over-quarter from $41.3 million in Q1 2021.
HUTCHMED (China) (HCM) Income towards Parent Company (2014 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has reported Income towards Parent Company for 8 consecutive years, with $61.0 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Income towards Parent Company rose 165.04% year-over-year to $61.0 million; the TTM figure through Dec 2022 stood at $61.0 million (down 40.38% YoY), while the FY2025 annual figure was $0.53, up 1225.0% from the prior year.
- Income towards Parent Company climbed to $61.0 million in Q2 2021 per HCM's latest filing, from $41.3 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $70.1 million in Q2 2018 and bottomed at -$99.4 million in Q2 2019.
- Historically, Income towards Parent Company has averaged $7.4 million across 5 years, with a median of $21.7 million in 2018.
- Annual changes were most pronounced in 2018 — Income towards Parent Company soared 74758.62% — and 2019, when it plunged 367.87%.
- HUTCHMED (China)'s Income towards Parent Company stood at $29000.0 in 2017, then jumped by 74758.62% to $21.7 million in 2018, then sank by 276.22% to -$38.3 million in 2019, then jumped by 160.21% to $23.0 million in 2020, then soared by 165.04% to $61.0 million in 2021.
- Business Quant data shows HCM's Income towards Parent Company at $61.0 million in Q2 2021, $41.3 million in Q1 2021, and $23.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | HUTCHMED (China) | 2.18 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 61.05 Mn |
| Mar 31, 2021 | 41.35 Mn |
| Jun 30, 2020 | 23.03 Mn |
| Mar 31, 2020 | 26.66 Mn |
| Dec 31, 2019 | -38.26 Mn |
| Sep 30, 2019 | -34.24 Mn |
| Jun 30, 2019 | -99.44 Mn |
| Mar 31, 2019 | 33.60 Mn |
| Dec 31, 2018 | 21.71 Mn |
| Sep 30, 2018 | 12.78 Mn |
| Jun 30, 2018 | 70.12 Mn |
| Mar 31, 2018 | -22.31 Mn |
| Dec 31, 2017 | 29,000.00 |
| Dec 31, 2016 | -248,000.00 |
| Jun 30, 2016 | 29.59 Mn |
| Dec 31, 2015 | -160,000.00 |
| Jun 30, 2015 | 23.42 Mn |
| Dec 31, 2014 | -3.06 Mn |